Search research articles
Contact Us
Filters
Showing results (111-120 of 265) with videos related to
Page
of 27
Sort By:
Endocrinology
|
October 5, 2017
Skeletal and Uterotrophic Effects of Endoxifen in Female Rats
Anne Gingery, Urszula T Iwaniec, Malayannan Subramaniam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2003
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors
Matthew P Goetz, Charles Erlichman, Anthony J Windebank, et al.
Cancers
|
September 9, 2022
Identification of Src Family Kinases as Potential Therapeutic Targets for Chemotherapy-Resistant Triple Negative Breast Cancer
Ishwar N Kohale, Jia Yu, Yongxian Zhuang, et al.
Journal of Clinical Pharmacology
|
March 31, 2022
Population Pharmacokinetics of Z-Endoxifen in Patients With Advanced Solid Tumors
Emily J Koubek, Andrew T Ralya, Thomas R Larson, et al.
International Journal of Oncology
|
June 10, 2016
Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy
Jae-Hyun Park, Miran Jang, Yunus Emre Tarhan, et al.
Breast Cancer Research and Treatment
|
March 16, 2006
Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52
James N Ingle, Vera J Suman, James A Mailliard, et al.
Clinical Breast Cancer
|
February 5, 2020
Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG)
Muaiad Kittaneh, Sunil Badve, Humberto Caldera, et al.
Molecular Cancer Therapeutics
|
September 1, 2018
ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer
Xinyi Tu, Mohamed M Kahila, Qin Zhou, et al.
Breast Cancer Research and Treatment
|
August 31, 2022
Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study
Grace M Choong, Savannah Liddell, Roberto A Leon Ferre, et al.
Plos One
|
May 24, 2014
The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeleton
Anne Gingery, Malayannan Subramaniam, Kevin S Pitel, et al.
Page
of 27
Search research articles
Search
Showing results (111-120 of 265) with videos related to
Sort By:
Page
of 27
Endocrinology
|
October 5, 2017
Skeletal and Uterotrophic Effects of Endoxifen in Female Rats
Anne Gingery, Urszula T Iwaniec, Malayannan Subramaniam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2003
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors
Matthew P Goetz, Charles Erlichman, Anthony J Windebank, et al.
Cancers
|
September 9, 2022
Identification of Src Family Kinases as Potential Therapeutic Targets for Chemotherapy-Resistant Triple Negative Breast Cancer
Ishwar N Kohale, Jia Yu, Yongxian Zhuang, et al.
Journal of Clinical Pharmacology
|
March 31, 2022
Population Pharmacokinetics of Z-Endoxifen in Patients With Advanced Solid Tumors
Emily J Koubek, Andrew T Ralya, Thomas R Larson, et al.
International Journal of Oncology
|
June 10, 2016
Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy
Jae-Hyun Park, Miran Jang, Yunus Emre Tarhan, et al.
Breast Cancer Research and Treatment
|
March 16, 2006
Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52
James N Ingle, Vera J Suman, James A Mailliard, et al.
Clinical Breast Cancer
|
February 5, 2020
Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG)
Muaiad Kittaneh, Sunil Badve, Humberto Caldera, et al.
Molecular Cancer Therapeutics
|
September 1, 2018
ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer
Xinyi Tu, Mohamed M Kahila, Qin Zhou, et al.
Breast Cancer Research and Treatment
|
August 31, 2022
Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study
Grace M Choong, Savannah Liddell, Roberto A Leon Ferre, et al.
Plos One
|
May 24, 2014
The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeleton
Anne Gingery, Malayannan Subramaniam, Kevin S Pitel, et al.
Page
of 27